A new HIV-preventive drug, lenacapavir, has demonstrated 100% efficacy and no safety concerns in a phase-3 trial involving young women in South Africa and Uganda. The twice-yearly injectable drug, developed by Gilead Sciences, Inc., showed zero HIV infections in the trial participants, compared to 39 and 16 infections in the groups receiving daily oral tablets Descovy and Truvada, respectively.
A groundbreaking HIV drug, Lenacapavir, could cost as little as $40 per year to manufacture, potentially revolutionizing the fight against the virus. Researchers estimate that the cost could be drastically reduced if generic versions are allowed, making the drug accessible to millions who currently cannot afford it.
A groundbreaking clinical trial in Africa has shown that a new injectable drug, lenacapavir, offers complete protection against HIV infection among young women. The trial, conducted by Gilead Sciences, has yielded promising results, with zero cases of HIV infection reported among women who received the drug. This breakthrough offers hope for a significant shift in HIV prevention strategies, particularly in Africa where the burden of the disease is highest.
